Mycidac-C Injection is an immunomodulator composed of heat-killed Mycobacterium W (Mw), indicated to treat NSCLC (Non-small Cell Lung Cancer) along with other anticancer agents leading to improvement in overall response, quality of life, and survival of patients. It contains the active ingredient Mitomycin C, a type of chemotherapy drug. It can be used with other chemotherapy drugs or as a standalone treatment. Patients should avoid live vaccines while receiving Mycidac-C Injection or several months after completing the treatment as the immune system may weaken. This medication can increase the risk of radiation-induced toxicity when combined with radiation therapy. Dose adjustments or close monitoring may be required in such patients.

Mycidac C Injection is used in the management of the following conditions:

• Non-small cell lung cancer
• Bladder cancer
• Melanoma
• Head and neck cancer
• Prostate cancer
• Optic nerve toxicity

The therapeutic effect of Mycidac-C Injection is primarily related to its ability to treat certain types of cancer. As an antineoplastic agent, it interferes with the DNA synthesis of cancer cells, ultimately leading to their death.

Inform your healthcare provider about all your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Mycidac-C and reduce effectiveness by causing undesirable side effects.

• Store in a refrigerator between 2°C and 8°C (36°F and 46°F).
• It should not be frozen.
• Keep it in its original packaging until it is ready to be used.
• Keep out of the reach of children and pets.

Mycidac-C Injection is a medication administered intravenously (IV) by a healthcare professional. It is important to follow the healthcare provider's instructions regarding the dosage and administration of medication. Do not double the dose to make up for missed doses.

Like all medications, Mycidac-C causes some side effects, although not everyone will experience them. 

Serious:

• Difficulty breathing
• Swelling of the face, lips, tongue, or throat, and hives
• Severe infections or flu-like symptoms
• Liver toxicity (abdominal pain and jaundice)
• Kidney toxicity (decreased urine output, swelling in the legs or feet)
• Low white blood cell count

Common:

• Injection site reactions such as pain, swelling, or redness
• Fatigue
• Nausea and vomiting
• Diarrhea
• Decreased appetite
• Hair loss
• Low white blood cell count

If you are prescribed Mycidac-C Injection or any other medication, it is important to carefully read and understand the warnings and precautions associated with the medication. Patients should be monitored for signs of an allergic reaction, such as rash, itching, or swelling, and should seek immediate medical attention if these symptoms occur. It should be used with caution in patients with severe renal impairment. Pregnant and breastfeeding women should discuss potential risk and benefit with a healthcare provider before taking this medication. Always maintain a healthy and balanced diet to support your overall health and well-being.

1. Cadila Pharmaceuticals, [Revised on 2021] [Accessed on 12th Aug 2021],  https://www.cadilapharma.com/research/worlds-first-innovation/
2. Krunal Kavathiya., et al. “Desmocollin-3 and Cancer”. Acta Scientific Cancer Biology 3.9 (2019): 19-28, https://www.actascientific.com/ASCB/pdf/ASCB-03-0155.pdf
3. Cancer Immunotherapy: Immune Suppression and Tumor Growth, Fourth edition, 2007, 507 to 536